An extensive research review of existing scientific findings involving bioactive compounds in Ganoderma Lucidum and the physiological effects of these compounds.
Certain cancer therapy agents can cause cardiotoxicity. Recent research reveals that Ganoderma spore oil demonstrates promising anti-cancer and cardioprotective effects.
Abstract
Inventor
The present invention relates to a method for preparing Ganoderma spore oil which is in the field of biotechnology. The method includes using Ganoderma spore powder and Ganoderma powder (obtained from grinding fruiting bodies) as raw materials, applying enzymatic Ganoderma sporoderm broken methods, one-step granulation, supercritical CO2 extraction method, as well as centrifugation and refining. The light yellow oleaginous substances obtained posses a variety of physiological functions such as strengthening immunity, protecting the liver and inhibiting tumor cell growth, etc. Ganoderma spore oil prepared with the present technology contains not only spore extracts, but also extracts from Ganoderma fruiting bodies and mycelium by CO2 supercritical extraction, with more types of triterpenoids. The inhibitory effects of Ganoderma spore oil is a onefold higher than spore oil prepared from the physical preparation of the sporoderm-broken spore. Meanwhile, the problem of spore oil spoilage arising from oxidation is solved due to the low peroxide value within Ganoderma spore oil, and thereby the quality of Ganoderma spore oil is greatly improved.
The anti-cancer components of Ganoderma lucidum possesses cardiovascular protective effect by regulating circular RNA expression
Yi-Zhen Xie1,2,*, Fenghua Yang3,*, Weijiang Tan3, Xiangmin Li1,4, Chunwei Jiao2, Ren Huang3, Burton B. Yang4,5
1 State Key Laboratory of Applied Microbiology Southern China, Guangdong Institute of Microbiology, Guangzhou, China
2 Guangdong Yuewei Edible Fungi Technology Co. Ltd., Guangzhou, China
3 Guangdong Laboratory Animals Monitoring Institute, Guangdong Provincial Key Laboratory of Laboratory Animals, Guangzhou, Guangdong, China
4 Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
5 Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada
Received: June 14, 2016 Accepted: August 12, 2016 Published: August 28, 2016
Enclosed below link to Article:
https://pubmed.ncbi.nlm.nih.gov/27713910/
INTRODUCTION
Complementary and alternative medicines have attracted increasing attention as disease treatments, adjuvants, and alternative supplements [1-4]. Medicinal mushrooms comprise a large proportion of these alternative products, among which Ganoderma lucidum is the most highly studied [5-8]. Preclinical studies have demonstrated anti-tumorigenic roles in a range of medicinal mushrooms [9-11]. A Cochrane meta- analysis showed that patients who had been administered Ganoderma lucidum alongside chemo/radiotherapy were more likely to respond positively compared to chemo/radiotherapy alone. These trials demonstrated improved immune functions as measured by increased CD3, CD4, and CD8 immune response cells [12]. In vitro, Ganoderma lucidum was also found to inhibit proliferation and induce apoptosis in ovarian, colon, and gastric cancer cell lines [13-15]. Ganoderma lucidum contains beta glucans and other polysaccharides which stimulate innate immunity and activate host dendritic cells [16, 17]. Ganoderma lucidum also produces a group of ganoderic acids, which have molecular structures that are similar to steroids [18, 19].